DRCAL the mice did not die.
CYGX0401 Anti-bacterial therapeutic compound against Sepsis, preclinical phase
Sepsis is a systemic inflammatory response to an infection in the circulatory system, which, if untreated, can lead to organ failure, hypo perfusion, hypotension and death. The CDC reports that the incidence of sepsis has increased approximately 8.7% annually from 164,000 cases (83 per 100,000 people) in 1979 to 660,000 cases (240 cases per 100,000 people) in 2000. Sepsis is the 11th leading cause of death (9.3% of all deaths) in the United States.
The most common form of sepsis is bacterial sepsis caused by infection by E. coli, S. aureus (staph) or Streptococcus (strep). Sepsis occurs in most individuals from trauma or major surgery. Immune compromised individuals are more susceptible to infection and thus to sepsis. CytoGenix scientists have used a proprietary genomic screening tool to identify bacterial genes that are critical to bacterial reproduction. Oligonucleotide (ODN) sequences to silence these genes have been developed.
Proof-of-concept studies in cells and in animals demonstrate the promising effectiveness of this compound. In mice studies, all the mice infected with E. coli sepsis survived when treated with the anti-bacterial sequences; the untreated groups died.
